Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the trial met its primary end point, demonstrating imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Townsend, William, Hiddemann, Wolfgang, Buske, Christian, Cartron, Guillaume, Cunningham, David, Dyer, Martin J.S., Gribben, John G., Phillips, Elizabeth H., Dreyling, Martin, Seymour, John F., Grigg, Andrew, Trotman, Judith, Lin, Tong-Yu, Hong, Xiao-Nan, Kingbiel, Dirk, Nielsen, Tina G., Knapp, Andrea, Herold, Michael, Marcus, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317485/
https://www.ncbi.nlm.nih.gov/pubmed/37404773
http://dx.doi.org/10.1097/HS9.0000000000000919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317485/
https://www.ncbi.nlm.nih.gov/pubmed/37404773
http://dx.doi.org/10.1097/HS9.0000000000000919

Ejemplares similares